HealthDay News — Only about 50 percent of adults with familial hypercholesterolemia (FH) are on statin therapy, and approximately 30 percent of those are taking high-intensity statins, according to a study published in Circulation.

Emily M. Bucholz, M.D., Ph.D., M.P.H., from Harvard Medical School in Boston, and colleagues estimated the prevalence rates of self-reported screening, awareness, and statin therapy among 42,471 U.S. adults with FH and with severe dyslipidemia.

The researchers found that the estimated U.S. prevalence of definite/probable FH and of severe dyslipidemia was 0.47 and 6.6 percent, respectively.

Among adults with definite/probable FH or severe dyslipidemia, the frequency of cholesterol screening and awareness was high (>80 percent); statin use was uniformly low among adults with definite/probable FH and with severe dyslipidemia (52.3 and 37.6 percent, respectively).

Of those with definite/probable FH on statins, only 30.3 percent were taking a high-intensity statin. Over time, there was an increase in the prevalence of statin use in adults with severe dyslipidemia (from 29.4 to 47.7 percent); however, the trend was no faster than that in the general population (from 5.7 to 17.6 percent).

Related Articles

Higher statin use was seen in association with older age, health insurance status, having a usual source of care, diabetes, hypertension, and having a personal history of early atherosclerotic cardiovascular disease.

“This study highlights an imperative to improve the frequency of cholesterol screening and statin prescription rates to better identify and treat this high-risk population,” the authors write.

Abstract/Full Text (subscription or payment may be required)